Pharmaceutical

FDA breakthrough status for Bluejay’s CHD therapy brelo...

The US FDA has granted breakthrough therapy designation to Bluejay Therapeutics’...

Catalent backs decentralised manufacture of Galapagos’ ...

Catalent has entered a strategic partnership with Galapagos to facilitate decent...

AI’s potential in the women’s health exciting, says Gat...

Panellists at the World Economic Forum 2025 Davos meeting discussed how artifici...

Key Lead Generation Providers and Technology Solutions ...

Discover the key lead generation providers and technology solutions for the phar...

Leading Sales and Marketing Intent Data, Database and D...

Discover leading Sales & Marketing Intent Data Solutions for the Pharmaceutical ...

FDA approves Amgen’s combo therapy for colorectal cancer

Amgen’s LUMAKRAS and Vectibix combination has received approval from the US FDA ...

Novo Nordisk’s Ozempic named in latest Medicare price n...

The negotiated prices of 15 Medicare Part D drugs, which include several blockbu...

Pfizer believes in the metaverse: will healthcare thaw ...

The metaverse hype is over, but developer Cassette Group has been working with P...

HEOR explained: Improving healthcare decisions with rea...

How longitudinal, closed claims data is advancing regulatory, epidemiology, and ...

Mega M&A at JP Morgan Conference 2025 — is biopharma M&...

Potential antitrust deregulation could foster a more favourable environment for ...

Charles River and Akron link to integrate cytokines int...

Charles River and Akron Bio have announced the integration of the latter’s CSS l...

FDA beats EMA to most approved new drugs in 2024

The FDA has narrowly beaten the European Medicines Agency (EMA) to the most appr...

COPD market to expand with AstraZeneca’s focus on biolo...

The upcoming release of Phase III Fasenra data in COPD in 2025 is expected to so...

JPM 2025: Lonza shares outlook on CHI exit and acquisit...

The Lonza CEO said the company is not under any pressure to exit the Capsules an...

Shionogi awarded $375m from HHS for preventative Covid-...

Shionogi’s S-892216 is being developed as a pre-exposure prophylaxis (PrEP) drug...